Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DSEA & CAIM

This article was originally published in The Tan Sheet

Executive Summary

Ten-member Corporate Alliance for Integrative Medicine merges with Dietary Supplement Education Alliance, giving DSEA an additional $65,000 in funding. CAIM was formed by a group of supplement companies in 1998 to jointly fund university research on supplements, develop educational initiatives for medical professionals and consumers. Merger is aimed at decreasing administrative duplication, encouraging industry cooperation on educational efforts. CAIM President Elliott Balbert, Natrol's president/CEO, was named DSEA president Feb. 5; he had been serving as the 50-member group's acting chairman since its creation in June (1"The Tan Sheet" June 18, 2001, p. 16)...

You may also be interested in...



New Supplement Marketer Alliance Creating Multi-Prong PR Campaign

A collaboration of dietary supplement trade groups and individual manufacturers aims to raise $5 mil. to support a multi-year media campaign featuring standard PR, advertising and the Internet.

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel